LRI Investments LLC Has $82,000 Stock Position in GSK PLC Sponsored ADR $GSK

LRI Investments LLC lowered its holdings in GSK PLC Sponsored ADR (NYSE:GSK) by 16.5% during the second quarter, HoldingsChannel.com reports. The institutional investor owned 2,138 shares of the pharmaceutical company’s stock after selling 424 shares during the period. LRI Investments LLC’s holdings in GSK were worth $82,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in the business. Trust Co. of Toledo NA OH grew its holdings in GSK by 2.7% in the 2nd quarter. Trust Co. of Toledo NA OH now owns 30,805 shares of the pharmaceutical company’s stock valued at $1,183,000 after buying an additional 797 shares during the last quarter. NBT Bank N A NY lifted its position in shares of GSK by 3.2% during the 2nd quarter. NBT Bank N A NY now owns 14,765 shares of the pharmaceutical company’s stock worth $567,000 after buying an additional 452 shares during the period. Prime Capital Investment Advisors LLC lifted its position in shares of GSK by 9.3% during the 2nd quarter. Prime Capital Investment Advisors LLC now owns 10,811 shares of the pharmaceutical company’s stock worth $415,000 after buying an additional 924 shares during the period. Valeo Financial Advisors LLC lifted its position in shares of GSK by 3.1% during the 2nd quarter. Valeo Financial Advisors LLC now owns 12,989 shares of the pharmaceutical company’s stock worth $499,000 after buying an additional 388 shares during the period. Finally, SOA Wealth Advisors LLC. lifted its position in shares of GSK by 252.1% during the 2nd quarter. SOA Wealth Advisors LLC. now owns 845 shares of the pharmaceutical company’s stock worth $32,000 after buying an additional 605 shares during the period. Institutional investors and hedge funds own 15.74% of the company’s stock.

Analysts Set New Price Targets

Several research firms recently commented on GSK. Wall Street Zen upgraded GSK from a “buy” rating to a “strong-buy” rating in a research report on Friday, September 5th. Weiss Ratings restated a “hold (c)” rating on shares of GSK in a research report on Wednesday, October 8th. Seven investment analysts have rated the stock with a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the stock has a consensus rating of “Reduce” and a consensus price target of $37.38.

GSK Stock Up 0.3%

Shares of GSK stock opened at $43.67 on Tuesday. The company has a quick ratio of 0.57, a current ratio of 0.87 and a debt-to-equity ratio of 1.07. GSK PLC Sponsored ADR has a 12 month low of $31.72 and a 12 month high of $45.59. The business has a fifty day simple moving average of $40.45 and a 200 day simple moving average of $38.89. The stock has a market cap of $88.83 billion, a PE ratio of 20.22, a price-to-earnings-growth ratio of 1.96 and a beta of 0.53.

GSK (NYSE:GSK) last announced its quarterly earnings data on Wednesday, July 30th. The pharmaceutical company reported $1.23 EPS for the quarter, topping analysts’ consensus estimates of $1.12 by $0.11. GSK had a return on equity of 49.22% and a net margin of 10.81%.The business had revenue of $10.64 billion during the quarter, compared to analysts’ expectations of $7.92 billion. During the same period in the previous year, the firm earned $0.43 earnings per share. The firm’s quarterly revenue was up 1.3% compared to the same quarter last year. GSK has set its FY 2025 guidance at 4.590-4.590 EPS. Research analysts predict that GSK PLC Sponsored ADR will post 4.14 EPS for the current year.

GSK Cuts Dividend

The firm also recently announced a quarterly dividend, which was paid on Thursday, October 9th. Shareholders of record on Friday, August 15th were paid a $0.4206 dividend. This represents a $1.68 dividend on an annualized basis and a yield of 3.9%. The ex-dividend date of this dividend was Friday, August 15th. GSK’s payout ratio is presently 78.24%.

GSK Company Profile

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.